LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

Search

Innoviva Inc

Fermé

SecteurSoins de santé

19.37 -0.15

Résumé

Variation du prix de l'action

24h

Actuel

Min

19.08

Max

19.47

Chiffres clés

By Trading Economics

Revenu

110M

64M

Ventes

12M

100M

P/E

Moyenne du Secteur

35.895

35.664

Marge bénéficiaire

63.508

Employés

127

EBITDA

111M

84M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+107.15% upside

Dividendes

By Dow Jones

Prochains Résultats

4 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

124M

1.3B

Ouverture précédente

19.52

Clôture précédente

19.37

Sentiment de l'Actualité

By Acuity

52%

48%

321 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Innoviva Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 sept. 2025, 22:41 UTC

Principaux Mouvements du Marché

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12 sept. 2025, 16:04 UTC

Principaux Mouvements du Marché

Upexi Shares Climb on Solana Gains

12 sept. 2025, 15:03 UTC

Principaux Mouvements du Marché

Allied Gaming & Entertainment Shares Surge Following Crypto Investments

12 sept. 2025, 20:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

12 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 sept. 2025, 20:09 UTC

Résultats

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12 sept. 2025, 19:23 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sept. 2025, 19:16 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sept. 2025, 19:03 UTC

Market Talk

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12 sept. 2025, 18:59 UTC

Market Talk

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12 sept. 2025, 18:38 UTC

Market Talk
Résultats

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12 sept. 2025, 18:33 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12 sept. 2025, 18:22 UTC

Market Talk

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12 sept. 2025, 16:56 UTC

Market Talk

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12 sept. 2025, 16:22 UTC

Résultats

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12 sept. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 sept. 2025, 16:19 UTC

Acquisitions, Fusions, Rachats

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 sept. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

12 sept. 2025, 16:11 UTC

Résultats

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12 sept. 2025, 15:37 UTC

Market Talk

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12 sept. 2025, 15:22 UTC

Market Talk

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12 sept. 2025, 15:07 UTC

Acquisitions, Fusions, Rachats

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 sept. 2025, 14:34 UTC

Market Talk

Russia Sanctions Put Bid Back in Oil -- Market Talk

12 sept. 2025, 14:10 UTC

Market Talk

Inflation Report Unlikely to Dissuade Canada From Rate Cut -- Market Talk

12 sept. 2025, 13:58 UTC

Market Talk

Dollar Could Rise if Fed Sounds Cautious on Rate Cuts -- Market Talk

12 sept. 2025, 13:58 UTC

Acquisitions, Fusions, Rachats

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Super Micro, Adobe, Microsoft, Figure Technology, and More -- Barrons.com

12 sept. 2025, 13:57 UTC

Résultats

AbbVie Stock Hit a Record on 'Big Win' for Blockbuster Drug. The Case for Buying In. -- Barrons.com

12 sept. 2025, 13:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 sept. 2025, 13:56 UTC

Market Talk

Canadian Dollar Faces Further Weakness Vs Non-U.S. Dollar Currencies -- Market Talk

12 sept. 2025, 13:54 UTC

Market Talk

U.S. Natural Gas Recovers Ground -- Market Talk

Comparaison

Variation de prix

Innoviva Inc prévision

Objectif de Prix

By TipRanks

107.15% hausse

Prévisions sur 12 Mois

Moyen 40.25 USD  107.15%

Haut 55 USD

Bas 26 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

4

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

18.57 / 18.75Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Neutral Evidence

Sentiment

By Acuity

321 / 371Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
help-icon Live chat